Paratek Pharmaceuticals Inc (PRTK):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Paratek Pharmaceuticals Inc (PRTK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9962
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Paratek Pharmaceuticals Inc (Paratek) is a biopharmaceutical company that develops and commercializes therapies based on tetracycline chemistry. Omadacycline (antibiotic), the company’s lead product candidate is an aminomethylcycline which acts against gram-negative, gram-positive, and atypical bacteria. It is investigating omadacycline in Phase III for the treatment of infections resistant to antibiotics: acute bacterial skin and skin structure infections (ABSSSI); community acquired bacterial pneumonia (CABP), urinary tract infections (UTI) and other community-acquired bacterial infections. The company is also developing sarecycline an oral, once-daily, antibiotic in Phase III for the treatment of acne and rosacea. Paratek is headquartered in Boston, Massachusetts, the US.

Paratek Pharmaceuticals Inc (PRTK) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Zai Lab Enters into Licensing Agreement with Paratek Pharma 11
Paratek Pharma Enters into Agreement with US Army Medical Research Institute of Infectious Diseases 12
Equity Offering 13
Paratek Pharma Raises USD50 Million in Public Offering of Shares 13
Paratek Pharma Plans to Raise up to USD250 Million in Public Offering of Securities 15
Paratek Pharma Plans to Raise up to USD50 Million in Public Offering 16
Paratek Pharma Raises USD63.53 Million in Public Offering of Shares 17
Paratek Pharma Raises USD76 Million in Public Offering of Shares 19
Paratek Pharma Raises USD93 Million in Private Placement 21
Paratek Pharma Withdraws IPO 23
Debt Offering 24
Paratek Pharma Raises USD140 Million in Private Placement of Notes Due 2024 24
Acquisition 25
Paratek Pharma May Sell Itself 25
Transcept Pharma Acquires Paratek Pharma 27
Paratek Pharmaceuticals Inc – Key Competitors 29
Paratek Pharmaceuticals Inc – Key Employees 30
Paratek Pharmaceuticals Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Strategy And Business Planning 32
Mar 24, 2017: Paratek Pharmaceuticals Opens New Office in King of Prussia 32
Financial Announcements 33
Nov 06, 2018: Paratek Pharmaceuticals reports third quarter 2018 financial results 33
Aug 02, 2018: Paratek Pharmaceuticals announces second quarter 2018 financial results 34
May 09, 2018: Paratek Pharmaceuticals Reports First Quarter 2018 Financial Results 36
Mar 01, 2018: Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Remains on Track for Commercial Launch by First Quarter 2019 37
Aug 02, 2017: Paratek Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical Update 38
May 04, 2017: Paratek Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Clinical Update 39
Mar 02, 2017: Paratek Pharmaceuticals Reports Full Year and Fourth Quarter 2016 Financial Results and Provides Clinical Update 40
Corporate Communications 41
Apr 13, 2018: Paratek Names Rolf K. Hoffman As Board Director 41
Oct 02, 2017: Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c) 42
Aug 01, 2017: Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 43
Jan 04, 2017: Paratek Pharmaceuticals Announces Promotion of Evan Loh, M.D. to the role of President and Chief Operating Officer 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Paratek Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Zai Lab Enters into Licensing Agreement with Paratek Pharma 11
Paratek Pharma Enters into Agreement with US Army Medical Research Institute of Infectious Diseases 12
Paratek Pharma Raises USD50 Million in Public Offering of Shares 13
Paratek Pharma Plans to Raise up to USD250 Million in Public Offering of Securities 15
Paratek Pharma Plans to Raise up to USD50 Million in Public Offering 16
Paratek Pharma Raises USD63.53 Million in Public Offering of Shares 17
Paratek Pharma Raises USD76 Million in Public Offering of Shares 19
Paratek Pharma Raises USD93 Million in Private Placement 21
Paratek Pharma Withdraws IPO 23
Paratek Pharma Raises USD140 Million in Private Placement of Notes Due 2024 24
Paratek Pharma May Sell Itself 25
Transcept Pharma Acquires Paratek Pharma 27
Paratek Pharmaceuticals Inc, Key Competitors 29
Paratek Pharmaceuticals Inc, Key Employees 30
Paratek Pharmaceuticals Inc, Other Locations 31
Paratek Pharmaceuticals Inc, Subsidiaries 31

List of Figures
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Paratek Pharmaceuticals Inc (PRTK):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Biglari Holdings Inc.:戦略・SWOT・企業財務分析
    Biglari Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary Biglari Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • The Dun & Bradstreet Corporation:企業の戦略・SWOT・財務情報
    The Dun & Bradstreet Corporation - Strategy, SWOT and Corporate Finance Report Summary The Dun & Bradstreet Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Airgain, Inc. (AIRG):企業の財務・戦略的SWOT分析
    Airgain, Inc. (AIRG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Chongqing Taiji Industry (Group) Co Ltd (600129):製薬・医療:M&Aディール及び事業提携情報
    Summary Chongqing Taiji Industry (Group) Co Ltd (Chongqing Taiji) is a provider of generic products. The company offers products such as traditional Chinese medicine, hospital products, OTC products, base products, and dietary supplement. It provides research and development, equipment, and manageme …
  • Revolution Medicines Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Revolution Medicines Inc (Revolution Medicines) is a drug development company that discovers and develops new medicines and therapies for cancer patients. The company’s programs include SHP2 Program, 4EBP1 Program and mTORC1 Program. It develops REVBLOCKS platform, an integrated suite of mod …
  • Semtech Corp (SMTC):企業の財務・戦略的SWOT分析
    Summary Semtech Corp (Semtech) is a supplier of analog and mixed-signal semiconductor products. The company provides products such as isolated power switches, UHD-SDI gearbox, wireless charging ICs, battery chargers, cable drivers, capacitive touch controllers, charge pump and current sink led drive …
  • Medtecs International Corp Ltd (546):企業の財務・戦略的SWOT分析
    Summary Medtecs International Corporation Ltd (Medtecs) is a medical device company that manufactures and distributes work wear apparels and medical device and consumables. The company's products include medical devices, healthcare textile work wear and hospitality textiles, among others. It also pr …
  • Cpp Group Plc (CPP):企業の財務・戦略的SWOT分析
    Summary Cpp Group Plc (CPP), is a provider of bespoke products and solutions. It offers flight disruption insurance, legal protection, autocare, assetcare and mobile phone insurance. It offers services such as airport angel, card rescue, card protection, packaged accounts and travel assistance. CPP …
  • Boralex Inc:発電所・企業SWOT分析
    Boralex Inc - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (execut …
  • Sysmex Corp (6869):医療機器:M&Aディール及び事業提携情報
    Summary Sysmex Corp (Sysmex) is a supplier of medical devices. It researches, develops, manufactures and sells instruments, reagents, and software applications that facilitate health checkups, treatment and disease management. The company offers diagnostic instruments, reagents and laboratory inform …
  • Astaldi Spa
    Astaldi Spa - Strategy, SWOT and Corporate Finance Report Summary Astaldi Spa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • DRB-HICOM Defense Technologies Sdn Bhd:企業の戦略・SWOT・財務情報
    DRB-HICOM Defense Technologies Sdn Bhd - Strategy, SWOT and Corporate Finance Report Summary DRB-HICOM Defense Technologies Sdn Bhd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • RayBiotech Inc:医療機器:M&Aディール及び事業提携情報
    Summary RayBiotech Inc (RayBiotech) is a life science company that provides proteins, antibodies and immunological kits. The company's product categories include antibody arrays, glycobiology arrays, protein arrays, phosphorylation arrays, elisa, functional assays, antibodies and custom recombinant …
  • Mack-Cali Realty Corp (CLI):企業の財務・戦略的SWOT分析
    Mack-Cali Realty Corp (CLI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Sete Brasil Participacoes SA:企業の戦略的SWOT分析
    Sete Brasil Participacoes SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • HITT Contracting Inc:企業の戦略的SWOT分析
    HITT Contracting Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • ITC Holdings Corp.:企業の発電所・SWOT分析2018
    ITC Holdings Corp. - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • Ezz Steel Company SAE:企業の戦略・SWOT・財務分析
    Ezz Steel Company SAE - Strategy, SWOT and Corporate Finance Report Summary Ezz Steel Company SAE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Green Dot Corporation:企業の戦略・SWOT・財務分析
    Green Dot Corporation - Strategy, SWOT and Corporate Finance Report Summary Green Dot Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Mission Pharmacal Company-製薬・医療分野:企業M&A・提携分析
    Summary Mission Pharmacal Company (Mission Pharmacal) is a pharmaceutical company, which develops, manufactures and markets prescription, over-the-counter, and dietary supplement products. It offers products for conditions related to women’s health, urology, pediatrics, and dermatology, among others …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆